Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
Orchestra BioMed (NASDAQ:OBIO) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs [Yahoo! Finance]
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock [Yahoo! Finance]
Orchestra BioMed (NASDAQ:OBIO) is now covered by analysts at TD Cowen. They set a "buy" rating and a $15.00 price target on the stock.